MedTrace Logo

CancerenD24 Screening as an Aid to the Clinician for the Diagnosis of Cancer

NCT06656728 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2024-10-24

No results posted yet for this study

Summary

The purpose of the researchers is to test whether the CancerenD24 index, an algorithm based on the quantitative value of CD24, CD11b, clinical and laboratory characteristics, developed in the laboratory can help in the early detection of a malignant disease in a population of healthy subjects.

Conditions

  • Cancer
  • Early Detection of Cancer

Interventions

OTHER

Blood-based liquid biopsy

Venous blood sample will be taken from the patient as part of the routine blood tests taken as part of the work at the Medical Center

Sponsors & Collaborators

  • Tel Aviv Medical Center

    collaborator OTHER

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-03
Primary Completion
2024-09-04
Completion
2027-09-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06656728 on ClinicalTrials.gov